CERo Therapeutics (CERO) Competitors $7.00 -0.22 (-3.05%) Closing price 07/30/2025 03:59 PM EasternExtended Trading$7.14 +0.14 (+1.93%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO vs. GOVX, CSCI, TRIB, SNPX, BCDA, IMCC, IBIO, PHIO, ALVR, and HOOKShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include GeoVax Labs (GOVX), COSCIENS Biopharma (CSCI), Trinity Biotech (TRIB), Synaptogenix (SNPX), BioCardia (BCDA), IM Cannabis (IMCC), iBio (IBIO), Phio Pharmaceuticals (PHIO), AlloVir (ALVR), and HOOKIPA Pharma (HOOK). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Its Competitors GeoVax Labs COSCIENS Biopharma Trinity Biotech Synaptogenix BioCardia IM Cannabis iBio Phio Pharmaceuticals AlloVir HOOKIPA Pharma GeoVax Labs (NASDAQ:GOVX) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Do insiders & institutionals hold more shares of GOVX or CERO? 6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 1.2% of GeoVax Labs shares are owned by company insiders. Comparatively, 12.7% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, GOVX or CERO? CERo Therapeutics has lower revenue, but higher earnings than GeoVax Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeoVax Labs$3.95M3.09-$24.99M-$3.65-0.21CERo TherapeuticsN/AN/A-$8.30MN/AN/A Do analysts rate GOVX or CERO? GeoVax Labs currently has a consensus target price of $8.88, suggesting a potential upside of 1,059.98%. CERo Therapeutics has a consensus target price of $45.00, suggesting a potential upside of 542.86%. Given GeoVax Labs' higher probable upside, analysts plainly believe GeoVax Labs is more favorable than CERo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is GOVX or CERO more profitable? CERo Therapeutics has a net margin of 0.00% compared to GeoVax Labs' net margin of -403.88%. CERo Therapeutics' return on equity of 0.00% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets GeoVax Labs-403.88% -408.80% -279.89% CERo Therapeutics N/A N/A -199.71% Which has more volatility & risk, GOVX or CERO? GeoVax Labs has a beta of 3.36, meaning that its stock price is 236% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Does the media favor GOVX or CERO? In the previous week, GeoVax Labs had 8 more articles in the media than CERo Therapeutics. MarketBeat recorded 9 mentions for GeoVax Labs and 1 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 1.89 beat GeoVax Labs' score of 0.56 indicating that CERo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment GeoVax Labs Positive CERo Therapeutics Very Positive SummaryCERo Therapeutics beats GeoVax Labs on 9 of the 14 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.79M$2.77B$5.65B$9.53BDividend YieldN/A1.78%4.71%4.03%P/E RatioN/A9.4930.2420.53Price / SalesN/A682.62449.4798.31Price / CashN/A159.7936.0158.40Price / Book-0.174.968.335.74Net Income-$8.30M$31.62M$3.25B$259.12M7 Day Performance-5.66%-3.12%-2.17%-2.61%1 Month Performance-27.31%9.83%7.95%8.58%1 Year Performance-97.76%-5.59%36.42%15.07% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo Therapeutics3.8776 of 5 stars$7.00-3.0%$45.00+542.9%-97.8%$2.79MN/A0.008Positive NewsGOVXGeoVax Labs1.8811 of 5 stars$0.82flat$8.88+982.3%-63.7%$13.06M$3.95M-0.2210Earnings ReportAnalyst ForecastAnalyst RevisionGap UpCSCICOSCIENS BiopharmaN/A$4.15-1.1%N/AN/A$13.06M$9.59M-0.7120TRIBTrinity Biotech0.8848 of 5 stars$0.72flatN/A-77.6%$13.00M$61.56M-0.25480Gap UpSNPXSynaptogenix0.0238 of 5 stars$9.21-8.9%N/A+71.9%$12.80MN/A-0.914BCDABioCardia3.4654 of 5 stars$2.30-1.7%$25.00+987.0%-28.0%$12.65M$60K-0.9940Positive NewsIMCCIM Cannabis0.1278 of 5 stars$3.08+1.3%N/A+3.1%$12.44M$39.44M-4.81340Gap DownIBIOiBio1.2293 of 5 stars$0.74+1.2%$5.00+579.7%-66.9%$12.15M$375K0.00100PHIOPhio Pharmaceuticals2.4308 of 5 stars$2.52+5.4%$14.00+455.6%-27.5%$12.09MN/A-0.3910Gap DownALVRAlloVirN/A$2.39-1.2%N/A-84.5%$12.05MN/A-0.12110Upcoming EarningsHigh Trading VolumeHOOKHOOKIPA Pharma3.0079 of 5 stars$0.97-6.9%$4.50+364.7%-84.5%$11.81M$43.95M-0.17160Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies GOVX Alternatives CSCI Alternatives TRIB Alternatives SNPX Alternatives BCDA Alternatives IMCC Alternatives IBIO Alternatives PHIO Alternatives ALVR Alternatives HOOK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERO) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
